KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer

Liao, Wenting, Overman, Michael J., Boutin, Adam T., Shang, Xiaoying, Zhao, Di, Dey, Prasenjit, Li, Jiexi, Wang, Guocan +19 more·2019·Cancer Cell
DOI 10.1016/j.ccell.2019.02.008

Cited by (619)

Items 201–300 of 619

  1. Combining RAS(ON) G12C-selective inhibitor with SHP2 inhibition sensitises lung tumours to immune checkpoint blockade
    Panayiotis Anastasiou, Christopher Moore, Sareena Rana, Mona Tomaschko, Claire E. Pillsbury, Andrea de Castro, Jesse Boumelha, Edurne Mugarza, Sophie de Carné Trécesson, Ania Mikolajczak et al. · 2024 · Nature Communications
  2. Targeting CXCR1/2: The medicinal potential as cancer immunotherapy agents, antagonists research highlights and challenges ahead
    Jinxin Che, Rui Song, Binhui Chen, Xiaowu Dong · 2019 · European Journal of Medicinal Chemistry
  3. N 6 -methyladenosine (m 6 A) in pancreatic cancer: Regulatory mechanisms and future direction
    Jian Li, Fangjuan Wang, Yongkang Liu, Huaizhi Wang, Bing Ni · 2021 · International Journal of Biological Sciences
  4. Hepatic interferon regulatory factor 8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti–programmed cell death protein‐1 therapy
    Hongxi Wu, Li Yan, Guangjiang Shi, Shijia Du, Xiaobin Wang, Wanli Ye, Zixuan Zhang, Ya Chu, Shuqian Ma, Dajia Wang et al. · 2022 · Hepatology
  5. Targeting RAS mutants in malignancies: successes, failures, and reasons for hope
    Hang Sheng Yang, Xinyi Zhou, Dongliang Fu, Chenqin Le, Jiafeng Wang, Quan Zhou, Xiangrui Liu, Ying Yuan, Kefeng Ding, Qian Xiao · 2022 · 癌症：英文版
  6. RAS signaling and immune cells: a sinister crosstalk in the tumor microenvironment
    Yongting Liu, Bin Xie, Qiong Chen · 2023 · Journal of Translational Medicine
  7. Cancer Nanomedicine Special Issue Review Anticancer Drug Delivery with Nanoparticles: Extracellular Vesicles or Synthetic Nanobeads as Therapeutic Tools for Conventional Treatment or Immunotherapy
    Maria Raffaella Zocchi, Francesca Tosetti, Roberto Benelli, Alessandro Delli Poggi · 2020 · Cancers
  8. Deep learning in digital pathology for personalized treatment plans of cancer patients
    Wen, Zhuoyu, Wang, Shidan, Yang, Donghan M., Xie, Yang, Chen, Mingyi, Bishop, Justin, Xiao, Guanghua · 2023 · Seminars in Diagnostic Pathology
  9. Immune Cell Migration to Cancer
    Allison T. Ryan, Minsoo Kim, Kihong Lim · 2024 · Cells
  10. Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments
    Shanshan Chen, Jingyi Tang, Fen Liu, Wěi Li, Ting Yan, Dangang Shangguan, Nong Yang, Dehua Liao · 2023 · Frontiers in Immunology
  11. Targeting crosstalk of STAT3 between tumor-associated M2 macrophages and Tregs in colorectal cancer
    Li-Li Huang, Yu Zhao, Mengying Shan, Sitong Wang, Jianhua Chen, Zhuqing Liu, Qing Xu · 2023 · Cancer Biology & Therapy
  12. KRAS mutations promote the intratumoral colonization of enterotoxigenic bacteroides fragilis in colorectal cancer through the regulation of the miRNA3655/SURF6/IRF7/IFNβ axis
    Yizhen Chen, Shaolin Liu, Song Tan, Yuanyuan Zheng, Yifan Chen, Changshun Yang, Shengtao Lin, Yulong Mi, Weihua Li · 2024 · Gut Microbes
  13. Diet, Microbiota, and Colorectal Cancer
    Tatiana P. Grazioso, Marta Brandt, Nabil Djouder · 2019 · iScience
  14. Integrated single-cell RNA-seq analysis identifies immune heterogeneity associated with KRAS/TP53 mutation status and tumor-sideness in colorectal cancers
    Xiaoyu Liu, Xu Xu, Zhuozhuo Wu, Qungang Shan, Ziyin Wang, Zhiyuan Wu, Xiaoyi Ding, Wei Huang, Zhongmin Wang · 2022 · Frontiers in Immunology
  15. Advances in immunotherapy for MMR proficient colorectal cancer
    Hazel Lote, Naureen Starling, Rille Pihlak, Marco Gerlinger · 2022 · Cancer Treatment Reviews
  16. Chemokines in progression, chemoresistance, diagnosis, and prognosis of colorectal cancer
    Qian Zou, Xue Lei, Aijing Xu, Ziqi Li, Qinglian He, Xiujuan Huang, Guangxian Xu, Faqing Tian, Yuanlin Ding, Wei Zhu · 2022 · Frontiers in Immunology
  17. How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation
    Qianyu Wang, Xiaofei Shen, Gang Chen, Junfeng Du · 2023 · International Journal of Cancer
  18. Opposing roles by KRAS and BRAF mutation on immune cell infiltration in colorectal cancer – possible implications for immunotherapy
    Sofia Edin, Björn Gylling, Xingru Li, Åsa Stenberg, Anna Löfgren‐Burström, Carl Zingmark, Bethany R. Van Guelpen, Ingrid Ljuslinder, Agnes Ling, Richard Palmqvist · 2023 · British Journal of Cancer
  19. Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer
    Mathieu J. F. Crupi, Zaid Taha, Thijs J. A. Janssen, Julia Petryk, Stephen Boulton, Nouf Alluqmani, Anna Jirovec, Omar Kassas, S. Khan, Sydney Vallati et al. · 2022 · Frontiers in Immunology
  20. Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer
    Sun Young Kim, Tae Won Kim · 2020 · ESMO Open
  21. Oncogenic PIK3CA recruits myeloid‐derived suppressor cells to shape the immunosuppressive tumour microenvironment in luminal breast cancer through the 5‐lipoxygenase‐dependent arachidonic acid pathway
    Xingchen Li, Guidong Chen, Fanchen Wang, Xiaojing Guo, Rui Zhang, Pengpeng Liu, Li Dong, Wenwen Yu, Huan Wang, Hailong Wang et al. · 2023 · Clinical and Translational Medicine
  22. First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer—the randomised METIMMOX trial
    Anne Hansen Ree, Jūratė Šaltytė Benth, Hanne Mari Hamre, Christian Kersten, Eva Hofsli, Marianne G. Guren, Halfdan Sørbye, Christin Johansen, Anne Negård, Tonje Bjørnetrø et al. · 2024 · British Journal of Cancer
  23. Expression Levels of Three Key Genes CCNB1, CDC20, and CENPF in HCC Are Associated With Antitumor Immunity
    Tengfei Si, Zhenlin Huang, Yuanhang Jiang, Abigail Walker-Jacobs, Shaqira Gill, Robert Hegarty, Mohammad Hamza, Shirin Elizabeth Khorsandi, Wayel Jassem, Nigel David Heaton et al. · 2021 · Frontiers in Oncology
  24. Nanoparticles augment the therapeutic window of RT and immunotherapy for treating cancers: pivotal role of autophagy
    Yuan-Hua Wu, Rong-Jane Chen, Hui‐Wen Chiu, Li‐Xing Yang, Yung‐Li Wang, Yuying Chen, Ya-Ling Yeh, Mei‐Yi Liao, Ying‐Jan Wang · 2022 · Theranostics
  25. Immunosuppressive Microenvironment Revealed by Immune Cell Landscape in Pre-metastatic Liver of Colorectal Cancer
    Dongqiang Zeng, Miaohong Wang, Jiani Wu, Siheng Lin, Zilan Ye, Rui Zhou, Gaofeng Wang, Jianhua Wu, Huiying Sun, Jianping Bin et al. · 2021 · Frontiers in Oncology
  26. The colorectal cancer microenvironment: Preclinical progress in identifying targets for cancer therapy
    Abdo Meyiah, Faez Iqbal Khan, Dia Aldeen Alfaki, Khaled Murshed, Afsheen Raza, Eyad Elkord · 2025 · Translational Oncology
  27. Microbiota-derived urocanic acid triggered by tyrosine kinase inhibitors potentiates cancer immunotherapy efficacy
    Mengying Zhang, Zhonghong Wei, Bin Wei, Changjie Lai, Gangfan Zong, Enxiang Tao, Minmin Fan, Yehua Pan, Bingyan Zhou, Luping Shen et al. · 2025 · Cell Host & Microbe
  28. Immunotherapy in colorectal cancer
    Parul Agarwal, Dung Thi Le, Patrick McKay Boland · 2021 · Advances in cancer research
  29. Recurrent somatic mutations as predictors of immunotherapy response
    Zoran Z. Gajic, Aditya S. Deshpande, Mateusz Legut, Marcin B. Imielinski, Neville E. Sanjana · 2022 · Nature Communications
  30. Neutrophils: Musketeers against immunotherapy
    Kashif Rafiq Zahid, Umar Raza, Soumya Tumbath, Lingxiang Jiang, Wenjuan Xu, Xiumei Huang · 2022 · Frontiers in Oncology
  31. BHLHE22 drives the immunosuppressive bone tumor microenvironment and associated bone metastasis in prostate cancer
    Chi Yin, Min Wang, Yingzhao Wang, Qijun Lin, Kai‐Yuan Lin, Hong Du, Chuandong Lang, Yuhu Dai, Xinsheng Peng · 2023 · Journal for ImmunoTherapy of Cancer
  32. Deciphering treatment resistance in metastatic colorectal cancer: roles of drug transports, EGFR mutations, and HGF/c-MET signaling
    Najah G. Albadari, Yang Xie, Wěi Li · 2024 · Frontiers in Pharmacology
  33. Emerging Trends in Gastrointestinal Cancer Targeted Therapies: Harnessing Tumor Microenvironment, Immune Factors, and Metabolomics Insights
    Sanchita Rauth, Mokenge Peter Malafa, Moorthy Palanimuthu Ponnusamy, Surinder K. Batra · 2024 · Gastroenterology
  34. Immune microenvironment and immunotherapy in hepatocellular carcinoma: mechanisms and advances
    Dong Xie, Yang Liu, Fangbiao Xu, Zhibo Dang, Mengge Li, Qinsheng Zhang, Zhongqin Dang · 2025 · Frontiers in Immunology
  35. Retinoic Acid Synthesis Deficiency Fosters the Generation of Polymorphonuclear Myeloid-Derived Suppressor Cells in Colorectal Cancer
    Hong-Wei Sun, Jing Chen, Wenchao Wu, Yanyan Yang, Yi-Tuo Xu, Xing-Juan Yu, Haitian Chen, Zilian Wang, Xiaojun Wu, Limin Zheng · 2020 · Cancer Immunology Research
  36. MTDH antisense oligonucleotides reshape the immunosuppressive tumor microenvironment to sensitize Hepatocellular Carcinoma to immune checkpoint blockade therapy
    Jing-Lei Wan, Biao Wang, Mei-Lan Wu, Jie Li, Ruo-Mu Gong, Li-Na Song, Hanshuo Zhang, Gui‐Qi Zhu, Shi-Ping Chen, Jialiang Cai et al. · 2022 · Cancer Letters
  37. Comprehensive analysis of expression profile and prognostic significance of interferon regulatory factors in pancreatic cancer
    Ke Zhang, Panling Xu, Yujie Li, Shu Dong, Huifeng Gao, Lianyu Chen, Hao Chen, Zhen Chen · 2022 · BMC Genomic Data
  38. PPARδ dysregulation of CCL20/CCR6 axis promotes gastric adenocarcinoma carcinogenesis by remodeling gastric tumor microenvironment
    Yi Liu, Daoyan Wei, Yasunori Deguchi, Weiguo Xu, Rui Tian, Fuyao Liu, Min Xu, Fei Mao, Donghui Li, Weidong Chen et al. · 2023 · Gastric Cancer
  39. A pan-KRAS degrader for the treatment of KRAS-mutant cancers
    Jie Yang, Qiao-Li Wang, Guannan Wang, Jia-Cong Ye, Zi-Qian Li, Jing-Yun Wang, Zhaohui Liang, Shuxin Li, Cong Sun, Wenting Liao et al. · 2024 · Cell Discovery
  40. Oncogenic KRAS drives immunosuppression of colorectal cancer by impairing DDX60-mediated dsRNA accumulation and viral mimicry
    Yi Zhou, Yaxin Zhang, Mingzhou Li, Tian Ming, Chao Zhang, Chengmei Huang, Jiexi Li, Fengtian Li, H.‐B. Li, Enen Zhao et al. · 2024 · Science Immunology
  41. The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment
    Hongzhi Sun, Bo Zhang, Haijun Li · 2020 · Technology in Cancer Research & Treatment
  42. Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis
    Snehangshu Kundu, Muhammad Akhtar Ali, Niklas Handin, L. Conway, V. Rendo, P. Artursson, Li-Qun He, D. Globisch, T. Sjöblom · 2021 · Journal of experimental & clinical cancer research : CR
  43. MYO1B enhances colorectal cancer metastasis by promoting the F-actin rearrangement and focal adhesion assembly via RhoA/ROCK/FAK signaling
    Lang Xie, Hongyun Huang, Zheng Zheng, Qian Yang, Shubo Wang, Yaoxu Chen, Jinlong Yu, Chunhui Cui · 2021 · Annals of Translational Medicine
  44. Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study
    Irene M. Shui, Xiao Qiao Liu, Qing Zhao, Seung Tae Kim, Yuan Ming Sun, Jennifer Holmes Yearley, Tasmiah Choudhury, Andrea L. Webber, Clemens Krepler, Răzvan Cristescu et al. · 2022 · Journal for ImmunoTherapy of Cancer
  45. Targeting the Tumor-Tumor Microenvironment Crosstalk
    Sunil Badve, Yesim Gökmen‐Polar · 2023 · Expert Opinion on Therapeutic Targets
  46. USP14-IMP2-CXCL2 axis in tumor-associated macrophages facilitates resistance to anti-PD-1 therapy in gastric cancer by recruiting myeloid-derived suppressor cells
    Li You, Qian Wang, Tianxue Zhang, Hongwei Xiao, Mengjiao Lv, Hong Lv, Li Deng, Xuyao Zhang, Yu Zhang · 2025 · Oncogene
  47. PTPN2 regulates the activation of KRAS and plays a critical role in proliferation and survival of KRAS-driven cancer cells
    Zhangsen Huang, Mingzhu Liu, Donghe Li, Yun Tan, Ruihong Zhang, Zhizhou Xia, Peihong Wang, Bo Jiao, Ping Liu, Ruibao Ren · 2020 · Journal of Biological Chemistry
  48. A CRISPR-Cas9 repressor for epigenetic silencing of KRAS
    Jingwen Liu, Meiyan Sun, Kwang Bog Cho, Xiang Gao, Bin Guo · 2020 · Pharmacological Research
  49. SFTPA1 is a potential prognostic biomarker correlated with immune cell infiltration and response to immunotherapy in lung adenocarcinoma
    Yuan Lü, Xixi Wu, Longshan Zhang, Mi Yean Yang, Xiaoqing Wang, Wenqi Huang, Hua Pan, Yuting Wu, Jihong Huang, Wenyu Liang et al. · 2021 · Cancer Immunology Immunotherapy
  50. Comprehensive analysis of the prognosis and immune infiltration for CXC chemokines in colorectal cancer
    Xi Yang, Yuanfeng Wei, Feng Sheng, Yirong Xu, Jiao Liu, Ling Gao, Ju Yang, Xinchen Sun, Junxing Huang, Qing Guo · 2021 · Aging
  51. PKCλ/ι inhibition activates an ULK2-mediated interferon response to repress tumorigenesis
    Juan F. Linares, Xiao Zhang, Anxo Martínez-Ordóñez, Ángeles Durán, Hiroto Kinoshita, Hiroaki Kasashima, Naoko Nakanishi, Yuki Nakanishi, Ryan Carelli, Luca Vincenzo Cappelli et al. · 2021 · Molecular Cell
  52. VPS9D1-AS1 overexpression amplifies intratumoral TGF-β signaling and promotes tumor cell escape from CD8+ T cell killing in colorectal cancer
    Lei Yang, Xichen Dong, Zheng Liu, Jinjing Tan, Xiaoxi Huang, Tao Wen, Hao Qu, Zhenjun Wang · 2022 · eLife
  53. Icariside II potentiates the anti-PD-1 antitumor effect by reducing chemotactic infiltration of myeloid-derived suppressor cells into the tumor microenvironment via ROS-mediated inactivation of the SRC/ERK/STAT3 signaling pathways
    Qing Kong, Mengyu Ma, Li Zhang, Suqing Liu, Shan He, Jinfeng Wu, Baojun Liu, Jingcheng Dong · 2022 · Phytomedicine
  54. Hyperactivation of β-catenin signal in hepatocellular carcinoma recruits myeloid-derived suppressor cells through PF4-CXCR3 axis
    Kaiting Wang, Jianmin Wu, Yang Zhao, Bo Jian Zheng, Siyun Shen, Ruiru Wang, Yani Zhang, Hongyang Wang, Lei Chen, Xinyao Qiu · 2024 · Cancer Letters
  55. Biomarker Identification through Proteomics in Colorectal Cancer
    Desirée Martín‐García, Marilina García‐Aranda, Maximino Redondo · 2024 · International Journal of Molecular Sciences
  56. Myeloid-derived suppressor cells in cancer: Current knowledge and future perspectives
    Sunanda Rajkumari, Jaspreet Singh, Usha Agrawal, Sandeep Agrawal · 2024 · International Immunopharmacology
  57. Major Vault Protein Promotes Hepatocellular Carcinoma Through Targeting Interferon Regulatory Factor 2 and Decreasing p53 Activity
    Haisheng Yu, Mengqi Li, Rui He, Peining Fang, Qiming Wang, Yi Yu, Fubing Wang, Li Zhou, Yi Zhang, Aidong Chen et al. · 2019 · Hepatology
  58. Disruption of CCR1-mediated myeloid cell accumulation suppresses colorectal cancer progression in mice
    Yoshiyuki Kiyasu, Kenji Kawada, Hideyo Hirai, Ryotaro Ogawa, Keita Hanada, Hideyuki Masui, Gen Nishikawa, Takamasa S. Yamamoto, Rei Mizuno, Yoshiro Itatani et al. · 2020 · Cancer Letters
  59. Malassezia in Inflammatory Bowel Disease: Accomplice of Evoking Tumorigenesis
    Qiyu Yang, Jing Ouyang, Damao Pi, Feng Li, Jiadan Yang · 2022 · Frontiers in Immunology
  60. Periplocin inhibits hepatocellular carcinoma progression and reduces the recruitment of MDSCs through AKT/NF-κB pathway
    Jiapeng Lin, Maohua Huang, Zhiting Sun, Lei Chen, Yuhe Lei, Yuqing Huang, Ming Qi, Shu-Ran Fan, Shou-Guo Chen, Chiwing Chung et al. · 2023 · Life Sciences
  61. Targeting myeloid-derived suppressor cells promotes antiparasitic T-cell immunity and enhances the efficacy of PD-1 blockade
    Chuanshan Zhang, Hui Wang, Tuerganaili Aji, Liang Li, Yinshi Li, Abidan Ainiwaer, Zibigu Rousu, Jing Li, Maolin Wang, Bingqing Deng et al. · 2024 · Nature Communications
  62. Impact of cancer cell-intrinsic features on neutrophil behavior
    Danique E. M. Duits, Karin E. de Visser · 2021 · Seminars in Immunology
  63. Chemokines as Regulators of Neutrophils: Focus on Tumors, Therapeutic Targeting, and Immunotherapy
    Raffaella Bonecchi, Alberto Mantovani, Sébastien Jaillon · 2022 · Cancers
  64. OLFM4 deficiency delays the progression of colitis to colorectal cancer by abrogating PMN-MDSCs recruitment
    Ziyang Chen, Xiaogang Zhang, Zhe Xing, Shuaijun Lv, Linxuan Huang, Jingping Liu, Shubiao Ye, Xinyao Li, Meiqi Chen, Shaowen Zuo et al. · 2022 · Oncogene
  65. Genomic Landscape of Advanced Solid Tumors in Circulating Tumor DNA and Correlation With Tissue Sequencing: A Single Institution's Experience
    Lorenzo Gerratana, Michael Movarek, Firas Wehbe, Neelima Katam, Devalingam Mahalingam, Jeannine Donahue, Ami N. Shah, Young Kwang Chae, Mary F. Mulcahy, Dean Tsarwhas et al. · 2022 · JCO Precision Oncology
  66. Bypassing anti-PD-(L)1 therapy: Mechanisms and management strategies
    Keywan Mortezaee, Jamal Majidpoor, Sajad Najafi, Davod Tasa · 2022 · Biomedicine & Pharmacotherapy
  67. Neutrophil and Colorectal Cancer
    Hideyuki Masui, Kenji Kawada, Kazutaka Obama · 2024 · International Journal of Molecular Sciences
  68. Oncogenic KRAS mutations drive immune suppression through immune-related regulatory network and metabolic reprogramming
    Lin Tian, Hui Li, Heran Cui, Chenchen Tang, Peiyan Zhao, Xinyue Wang, Ying Cheng · 2025 · Cell Death and Disease
  69. Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma
    Tao T. Fan, Yu Liu, Hengchang Liu, Liyu Wang, He Tian, Yujia Zheng, Bo Jian Zheng, Liyan Xue, Fengwei Tan, Qi Xue et al. · 2021 · Cancer Immunology Immunotherapy
  70. Caspase‐6/Gasdermin C‐Mediated Tumor Cell Pyroptosis Promotes Colorectal Cancer Progression Through CXCL2‐Dependent Recruitment of Myeloid‐Derived Suppressor Cells
    Hanchao Gao, Yikun Yao, Weilong Li, Zigan Xu, Wenjun Hu, Ke-Wang Luo, Peishan Chen, Wanjing Shang, Shaodong Luan, Guojun Shi et al. · 2025 · Advanced Science
  71. miR‐587 promotes cervical cancer by repressing interferon regulatory factor 6
    Yuefang Ren, Jie Dong, Pingya He, Yufei Liang, Lifang Wu, Jiajian Wang, Boliang Chu · 2020 · The Journal of Gene Medicine
  72. Recombinant KRAS G12D Protein Vaccines Elicit Significant Anti-Tumor Effects in Mouse CT26 Tumor Models
    Yuhua Wan, Yan Zhang, Gengchong Wang, Patrick Malonza Mwangi, Huaman Cai, Rongxiu Li · 2020 · Frontiers in Oncology
  73. Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors
    Fernando Fernández-García, Ana Fernández-Rodríguez, Coral Fustero Torre, Elena Piñeiro-Yáñez, Haiyun Wang, Carmen G. Lechuga, Sergio Callejas, Rebeca Álvarez, Alejandra López-García, Laura Esteban-Burgos et al. · 2024 · Proceedings of the National Academy of Sciences
  74. Evolution of direct RAS inhibitors: from undruggable target to clinical breakthroughs
    Xia Wang, Jing Wu, Aotian Xiao, Jie Wang, Jun Tian · 2025 · Molecular Cancer
  75. DCLK1 Suppresses Tumor-Specific Cytotoxic T Lymphocyte Function Through Recruitment of MDSCs via the CXCL1-CXCR2 Axis
    Rui Yan, Jian Jian Li, Zeru Xiao, Xiaona Fan, Heshu Liu, Ying Xu, Ruya Sun, Jian Liu, Jiannan Yao, Guangyu An et al. · 2022 · Cellular and Molecular Gastroenterology and Hepatology
  76. Aryl hydrocarbon receptor nuclear translocator limits the recruitment and function of regulatory neutrophils against colorectal cancer by regulating the gut microbiota
    Yujing Bi, Qiuli Yang, Zhengchao Li, Yuexin Wang, Yufei Wang, Anna Jia, Zhiyuan Pan, Ruifu Yang, Guangwei Liu · 2023 · Journal of Experimental & Clinical Cancer Research
  77. Omics-based molecular classifications empowering in precision oncology
    Zhaokai Zhou, Ting Lin, Shuang Chen, Ge Zhang, Yudi Xu, Haijiao Zou, Aoyang Zhou, Yuyuan Zhang, Siyuan Weng, Xinwei Han et al. · 2024 · Cellular Oncology
  78. CXCR1/2 antagonism inhibits neutrophil function and not recruitment in cancer
    Jeff Kwak, Helena Q. Nguyen, Alex Camai, Grace M. Huffman, Surapat Mekvanich, Naia N. Kenney, Xiaodong Zhu, Timothy W. Randolph, A. McGarry Houghton · 2024 · OncoImmunology
  79. MAZ promotes tumor proliferation and immune evasion in lung adenocarcinoma
    Yan Chen, Xinsheng Zhu, Jue Wang, Junjie Hu, Jing Zhang, Xun Zhang, Lu Han, Huansha Yu, Hai Hu, Ke Fei et al. · 2024 · Oncogene
  80. From Subtypes to Solutions: Integrating CMS Classification with Precision Therapeutics in Colorectal Cancer
    Xinyi Ding, Hao Huang, Fang Zhang, Jingting Jiang · 2024 · Current Treatment Options in Oncology
  81. Shaping the battlefield: EGFR and KRAS tumor mutations’ role on the immune microenvironment and immunotherapy responses in lung cancer
    Bassel Alsaed, Nina Bobik, Hanna K. Laitinen, Tanvi Nandikonda, Ilkka Ilonen, Heidi M. Haikala · 2025 · Cancer and Metastasis Reviews
  82. Development of an IFNγ response‐related signature for predicting the survival of cutaneous melanoma
    Baohui Hu, Qian Wei, Xueping Li, Mingyi Ju, Lin Wang, Chenyi Zhou, Lianze Chen, Zinan Li, Minjie Wei, Miao He et al. · 2020 · Cancer Medicine
  83. Mesoporous nanodrug delivery system: a powerful tool for a new paradigm of remodeling of the tumor microenvironment
    Yinhui Hang, Yanfang Liu, Zhaogang Teng, Xiongfeng Cao, Haitao Zhu · 2023 · Journal of Nanobiotechnology
  84. Clonal evolution and immune evasion in posttransplantation relapses
    Luca Vago · 2019 · Hematology
  85. GOLM1 Drives Colorectal Cancer Metastasis by Regulating Myeloid-derived Suppressor Cells
    Yunzhi Dang, Jiao Yu, Shuhong Zhao, Long Guo Jin, Ximing Cao, Qing Wang · 2021 · Journal of Cancer
  86. PDP1 promotes KRAS mutant colorectal cancer progression by serving as a scaffold for BRAF and MEK1
    Ming Yuan, Chi Zhang, Shaopeng Chen, Shubiao Ye, Huashan Liu, Haoxian Ke, Junfeng Huang, Guanzhan Liang, Runfeng Yu, Tuo Hu et al. · 2024 · Cancer Letters
  87. Molecular subtypes of colorectal cancer in the era of precision oncotherapy: Current inspirations and future challenges
    Qin Dang, Lulu Zuo, Xinru Hu, Zhaokai Zhou, Shuang Chen, Shutong Liu, Yuhao Ba, Anning Zuo, Hui Xu, Siyuan Weng et al. · 2024 · Cancer Medicine
  88. MicroRNA-enriched exosome as dazzling dancer between cancer and immune cells
    Chou‐Yi Hsu, Abdulrahman T. Ahmed, Pooja Bansal, Ahmed M. Hjazi, Hussein Riyadh Abdul Kareem Al‐Hetty, Maytham Talib Qasim, Ibrokhim B. Sapaev, Mahamedha Deorari, Yasser Fakri Mustafa, Ahmed Elawady · 2024 · Journal of Physiology and Biochemistry
  89. Oncolytic Virotherapy: The Cancer Cell Side
    Marcelo Ehrlich, Eran Bacharach · 2021 · Cancers
  90. Cathepsin C promotes colorectal cancer metastasis by regulating immune escape through upregulating CSF1
    Yunzhi Dang, Xiao-Jiao CHEN, Jiao Yu, Shu-Hong ZHAO, Ximing Cao, Qing WANG · 2023 · Neoplasma
  91. Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy
    Jiangjun Cao, Zhe Zhang, Li Zhou, Maochao Luo, Lei Li, Bowen Li, Edouard Collins Nice, Weifeng He, Shaojiang Zheng, Canhua Huang · 2023 · MedComm
  92. Deubiquitinase USP4 suppresses antitumor immunity by inhibiting IRF3 activation and tumor cell-intrinsic interferon response in colorectal cancer
    Yi Zhou, Huali Li, Yaxin Zhang, Enen Zhao, Chengmei Huang, Xingyan Pan, Feng Shu, Zhihao Liu, Na Tang, Fengtian Li et al. · 2024 · Cancer Letters
  93. Arachidonic acid released by PIK3CA mutant tumor cells triggers malignant transformation of colonic epithelium by inducing chromatin remodeling
    Baoyu He, Qingli Bie, Rou Zhao, Yugang Yan, Guanjun Dong, Baogui Zhang, Sen Wang, Wenrong Xu, Dongxing Tian, Yujun Hao et al. · 2024 · Cell Reports Medicine
  94. Metronomic chemotherapy in cancer treatment: new wine in an old bottle
    Huailiang Wu, Han-Xing Zhou, Limin Chen, Shu-sen Wang · 2024 · Theranostics
  95. Good cops turn bad: The contribution of neutrophils to immune-checkpoint inhibitor treatment failures in cancer
    Huajia Zhang, A. McGarry Houghton · 2020 · Pharmacology & Therapeutics
  96. FOLR2+ macrophages in cancer: allies or enemies
    Decheng Jiang, Ruiling Xiao, Jialu Bai, Xing Wang, Yuan Fang, Jianzhou Liu, Xiaohan Wang, Ming Cui, Lei You, Yupei Zhao · 2025 · Cell Communication and Signaling
  97. A STING-related prognostic score predicts high-risk patients of colorectal cancer and provides insights into immunotherapy
    Si-Yuan Chen, Siyu Chen, Wanjing Feng, Ziteng Li, Yixiao Luo, Xiaodong Zhu · 2021 · Annals of Translational Medicine
  98. Targeting the “undruggable” RAS with biologics
    Michael Whaby, Imran Khan, John P. O’Bryan · 2022 · Advances in cancer research
  99. HOXB9 Overexpression Promotes Colorectal Cancer Progression and Is Associated with Worse Survival in Liver Resection Patients for Colorectal Liver Metastases
    Eirini Martinou, Carla S. Möller‐Levet, Dimitrios Karamanis, Izhar Bagwan, Angeliki M. Angelidi · 2022 · International Journal of Molecular Sciences
  100. A humanized 4-1BB-targeting agonistic antibody exerts potent antitumor activity in colorectal cancer without systemic toxicity
    Liansheng Cheng, Yongfeng Cheng, Wenting Liu, Aolin Shen, Dayan Zhang, Tingjuan Xu, Yin Wu, Min Cheng, Xiaopeng Ma, Feng‐Rong Wang et al. · 2022 · Journal of Translational Medicine